Akebia Therapeutics (AKBA) Long-Term Debt Repayments: 2016-2025
Historic Long-Term Debt Repayments for Akebia Therapeutics (AKBA) over the last 5 years, with Mar 2025 value amounting to $462,000.
- Akebia Therapeutics' Long-Term Debt Repayments fell 98.74% to $462,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $37.6 million, marking a year-over-year decrease of 45.35%. This contributed to the annual value of $37.1 million for FY2024, which is 15.93% up from last year.
- As of Q1 2025, Akebia Therapeutics' Long-Term Debt Repayments stood at $462,000, which was up 46,300.00% from -$1,000 recorded in Q4 2024.
- Akebia Therapeutics' Long-Term Debt Repayments' 5-year high stood at $36.7 million during Q1 2024, with a 5-year trough of -$1,000 in Q4 2024.
- Over the past 3 years, Akebia Therapeutics' median Long-Term Debt Repayments value was $8.0 million (recorded in 2023), while the average stood at $9.9 million.
- Over the last 5 years, Akebia Therapeutics' Long-Term Debt Repayments had its largest YoY gain of 129.54% in 2024, and its largest YoY loss of 100.01% in 2024.
- Akebia Therapeutics' Long-Term Debt Repayments (Quarterly) stood at $33.0 million in 2022, then reached $8.0 million in 2023, then plummeted by 100.01% to -$1,000 in 2024, then plummeted by 98.74% to $462,000 in 2025.
- Its Long-Term Debt Repayments was $462,000 in Q1 2025, compared to -$1,000 in Q4 2024 and $374,000 in Q2 2024.